A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2019
Price : $35 *
At a glance
- Drugs Vobarilizumab (Primary) ; Vobarilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Ablynx
- 31 Aug 2018 Biomarkers information updated
- 23 Oct 2014 Results published in an Ablynx media release.
- 21 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History